131 related articles for article (PubMed ID: 34852379)
1. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
Selvadurai MV; Riaz M; Xie S; Tonkin AM; McNeil JJ; Lacaze P; Hamilton JR
Thromb Haemost; 2022 Jul; 122(7):1130-1138. PubMed ID: 34852379
[TBL] [Abstract][Full Text] [Related]
2. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
3. Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902.
Li S; Tarlac V; Christanto RBI; French SL; Hamilton JR
Platelets; 2021 Oct; 32(7):988-991. PubMed ID: 32819173
[TBL] [Abstract][Full Text] [Related]
4. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
5. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.
Denorme F; Armstrong ND; Stoller ML; Portier I; Tugolukova EA; Tanner RM; Montenont E; Bhatlekar S; Cody M; Rustad JL; Ajanel A; Tolley ND; Murray DC; Boyle JL; Nieman MT; McKenzie SE; Yost CC; Lange LA; Cushman M; Irvin MR; Bray PF; Campbell RA
J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37471144
[TBL] [Abstract][Full Text] [Related]
6. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
French SL; Thalmann C; Bray PF; Macdonald LE; Murphy AJ; Sleeman MW; Hamilton JR
Blood Adv; 2018 Jun; 2(11):1283-1293. PubMed ID: 29884748
[TBL] [Abstract][Full Text] [Related]
7. Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population.
Lewis JP; Riaz M; Xie S; Polekhina G; Wolfe R; Nelson M; Tonkin AM; Reid CM; Murray AM; McNeil JJ; Shuldiner AR; Lacaze P
Clin Pharmacol Ther; 2020 Dec; 108(6):1289-1298. PubMed ID: 32562573
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
Tricoci P; Neely M; Whitley MJ; Edelstein LC; Simon LM; Shaw C; Fortina P; Moliterno DJ; Armstrong PW; Aylward P; White H; Van de Werf F; Jennings LK; Wallentin L; Held C; Harrington RA; Mahaffey KW; Bray PF
Blood Cells Mol Dis; 2018 Sep; 72():37-43. PubMed ID: 30055940
[TBL] [Abstract][Full Text] [Related]
9. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
[TBL] [Abstract][Full Text] [Related]
10. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
Edelstein LC; Simon LM; Lindsay CR; Kong X; Teruel-Montoya R; Tourdot BE; Chen ES; Ma L; Coughlin S; Nieman M; Holinstat M; Shaw CA; Bray PF
Blood; 2014 Nov; 124(23):3450-8. PubMed ID: 25293779
[TBL] [Abstract][Full Text] [Related]
11. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the
Ningtyas D; Thomson RJ; Tarlac V; Nagaraj SH; Hoy W; Mathews JD; Foote SJ; Gardiner EE; Hamilton JR; McMorran BJ
Front Genet; 2020; 11():432. PubMed ID: 32425989
[TBL] [Abstract][Full Text] [Related]
14. A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.
Rodriguez BAT; Bhan A; Beswick A; Elwood PC; Niiranen TJ; Salomaa V; ; Trégouët DA; Morange PE; Civelek M; Ben-Shlomo Y; Schlaeger T; Chen MH; Johnson AD
Am J Hum Genet; 2020 Aug; 107(2):211-221. PubMed ID: 32649856
[TBL] [Abstract][Full Text] [Related]
15. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.
Wong PC; Seiffert D; Bird JE; Watson CA; Bostwick JS; Giancarli M; Allegretto N; Hua J; Harden D; Guay J; Callejo M; Miller MM; Lawrence RM; Banville J; Guy J; Maxwell BD; Priestley ES; Marinier A; Wexler RR; Bouvier M; Gordon DA; Schumacher WA; Yang J
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053157
[TBL] [Abstract][Full Text] [Related]
16. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
17. PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Wilson SJ; Ismat FA; Wang Z; Cerra M; Narayan H; Raftis J; Gray TJ; Connell S; Garonzik S; Ma X; Yang J; Newby DE
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):448-456. PubMed ID: 29269513
[TBL] [Abstract][Full Text] [Related]
18. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
19. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
[TBL] [Abstract][Full Text] [Related]
20. Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques.
Wickham LA; Sitko G; Stranieri-Michener M; Handt L; Basso A; Fried S; Chu L; Maderia M; Owens K; Castriota G; Chen Z; Metzger JM; Imbriglio J; Wang X; Cai TQ
Thromb Res; 2016 Sep; 145():133-9. PubMed ID: 27318768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
